Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III drugs for Colorectal Cancer have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Botensilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Botensilimab overview
AGEN-1181 is under development for the treatment of solid tumors including angiosarcoma and microsatellite stable tumors but not limited to PD-1-refractory non-small-cell lung cancer, ovarian cancer, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, gastric cancer, breast cancer, prostate cancer, bladder cancer, head & neck SCC and MSS-colorectal cancer, renal cell carcinoma, metastatic castration-resistant prostate cancer (mCRPC), endometrial cancer, cervical cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, leiomyosarcoma, melanoma and colorectal cancer. The therapeutic candidate is administered through intravenous route. It is developed based on retrocyte display technology. The therapeutic candidate acts by targeting cytotoxic T lymphocyte-associated molecule-4 (CTLA-4).
Agenus overview
Agenus is a biotechnology company. It is advancing therapies targeting cancer through a pipeline of immunological agents. The company’s portfolio includes several advanced platforms and programs designed to drive innovation in immuno-oncology (I-O). These consist of multiple proprietary antibody discovery platforms; antibody candidate programs such as botensilimab and balstilimab; a saponin-based vaccine adjuvant platform centered around the STIMULON cultured plant cell (CPC) QS-21 adjuvant and a pipeline of novel allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and other immune-mediated diseases. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Botensilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
